WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H329216
CAS#: 496-67-3
Description: Bromisoval, also known as bromovalerylurea, is a bromide-containing sedative-hypnotic that is occasionally combined with non-steroidal anti-inflammatory drugs in over-the-counter products. Bromisoval suppresses expression of many kinds of pro- and anti-inflammatory mediators in LPS- or interferon-γ activated alveolar and peritoneal macrophages. Bromisoval is used to treat anxiety.
Hodoodo Cat#: H329216
Name: Bromisoval
CAS#: 496-67-3
Chemical Formula: C6H11BrN2O2
Exact Mass: 222.00
Molecular Weight: 223.070
Elemental Analysis: C, 32.31; H, 4.97; Br, 35.82; N, 12.56; O, 14.34
Synonym: Bromisoval; bromovalerylurea; Isobromyl; Bromaral; BRN 1773255; BRN-1773255; BRN1773255
IUPAC/Chemical Name: 2-bromo-N-carbamoyl-3-methylbutanamide
InChi Key: CMCCHHWTTBEZNM-UHFFFAOYSA-N
InChi Code: InChI=1S/C6H11BrN2O2/c1-3(2)4(7)5(10)9-6(8)11/h3-4H,1-2H3,(H3,8,9,10,11)
SMILES Code: O=C(N)NC(C(Br)C(C)C)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 223.07 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Maeda H, Oritani S, Nagai K, Tanaka T, Tanaka N. Detection of bromisovalum from the bone marrow of skeletonized human remains: a case report with a comparison between gas chromatography/mass spectrometry (GC/MS) and high-performance liquid chromatography/mass spectrometry (LC/MS). Med Sci Law. 1997 Jul;37(3):248-53. PubMed PMID: 9264232.
2: Yanagisawa K. [Transition of Psychotropic Drugs in Japanese Pharmacopoeia (JP) (Part 16). Transitions in the Standards and Test Methods of Bromovalerylurea in JP V (1932) and JP X VI (2011), and Comparison with Deutsches Arzneibuch]. Yakushigaku Zasshi. 2015;50(2):143-58. Japanese. PubMed PMID: 27149780.
3: Yokose C, Nakai N, Katoh N. Maculopapular-type drug eruption caused by Coughcode(®)-N combination tablets. Allergol Int. 2013 Dec;62(4):519-21. doi: 10.2332/allergolint.13-LE-0558. PubMed PMID: 24060762.
4: Kuo CY, Liu CM, Chang LR. Psychosis associated with bromvalerylurea abuse in a patient with traumatic brain injury. Gen Hosp Psychiatry. 2012 May-Jun;34(3):e3-4. doi: 10.1016/j.genhosppsych.2011.10.010. PubMed PMID: 22154658.
5: Kikuchi S, Nishihara T, Kawasaki S, Abe N, Kuwabara J, Choudhury ME, Takahashi H, Yano H, Nagaro T, Watanabe Y, Aibiki M, Tanaka J. The ameliorative effects of a hypnotic bromvalerylurea in sepsis. Biochem Biophys Res Commun. 2015 Apr 3;459(2):319-26. doi: 10.1016/j.bbrc.2015.02.111. PubMed PMID: 25732089.
6: Armstrong D, Schep L. Comparing bromism with methyl bromide toxicity. Clin Toxicol (Phila). 2009 Apr;47(4):371-2; author reply 372. doi: 10.1080/15563650902802544. PubMed PMID: 19360507.
7: Tanaka M, Sasaki Y. [Q & A. A patient brought in a comatose state, displaying acute hepatic disorder and an area of high absorption in the stomach in CT images]. Nihon Shokakibyo Gakkai Zasshi. 2011 Apr;108(4):665-6, 669. Japanese. PubMed PMID: 21696021.
8: Cantrell FL, Minns A. Cybersuicide with "homemade Valium". Clin Toxicol (Phila). 2011 Jan;49(1):56. doi: 10.3109/15563650.2010.550585. PubMed PMID: 21288154.
9: Mulders TM, Bergman DJ, Poll-The BT, Smit GP, Breimer DD, Mulder GJ, Duran M, Smeitink JA. Abnormal glutathione conjugation in patients with tyrosinaemia type I. J Inherit Metab Dis. 1997 Aug;20(4):473-85. PubMed PMID: 9266383.
10: Kowa H, Shimizu Y, Matsushima E, Tabata M. [A case of acute bromvalerylurea intoxication: clinical course and alteration in serum bromvalerylurea concentration]. No To Shinkei. 2006 Apr;58(4):323-8. Japanese. PubMed PMID: 16681262.
11: Fukai Y, Ohta S. [Hypnotic (barbiturate, non-barbiturate)]. Nihon Rinsho. 2004 Dec;62 Suppl 12:364-7. Review. Japanese. PubMed PMID: 15658339.
12: Takahashi M, Kinoshita H, Nishiguchi M, Kasuda S, Ouchi H, Minami T, Matsui K, Yamamura T, Motomura H, Ohta T, Komeda M, Aoki Y, Ohtsu N, Yoshida S, Adachi N, Ameno K, Hishida S. Application of energy dispersive X-ray fluorescent spectrometry (EDXRF) in drug-related cases. Leg Med (Tokyo). 2009 Apr;11 Suppl 1:S411-2. doi: 10.1016/j.legalmed.2009.01.077. PubMed PMID: 19251460.
13: Yan MT, Yang SS, Chu HY, Lin SH. Ataxia associated with spurious hyperchloremia: the one behind the scene. Am J Emerg Med. 2009 Jul;27(6):752.e1-3. doi: 10.1016/j.ajem.2008.09.044. PubMed PMID: 19751639.
14: Hori Y, Fujisawa M, Shimada K, Hirose Y, Yoshioka T. Method for screening and quantitative determination of serum levels of salicylic Acid, acetaminophen, theophylline, phenobarbital, bromvalerylurea, pentobarbital, and amobarbital using liquid chromatography/electrospray mass spectrometry. Biol Pharm Bull. 2006 Jan;29(1):7-13. PubMed PMID: 16394500.
15: Lin JN, Lin HL, Huang CK, Lai CH, Chung HC, Liang SH, Lin HH. Myoclonic jerks due to acute bromovalerylurea intoxication. Clin Toxicol (Phila). 2008 Nov;46(9):861-3. doi: 10.1080/15563650802020361. PubMed PMID: 18668386.
